Antisoma sells US rights to oral fludarabine for $65 million
This article was originally published in Scrip
Executive Summary
Antisoma has sold the US rights to oral fludarabine, for chronic lymphocytic leukaemia, to Sanofi-Aventis for $65 million to develop its lead programmes ASA404 and AS1413 until mid-2011.